[Combination of clofibrate and phenformin in the treatment of endogenous hypertriglyceridaemia (author's transl)].
Combined treatment with clofibrate and phenformin increased the lipid-lowering effect of clofibrate monotherapy in 15 patients with endogenous hypertriglyceridaemia significantly by ca. 10%. The therapeutic success was shown by a reduction in LDL-cholesterol and an additional reduction in VLDL-triglycerides. A clofibrate-induced rise in LDL-cholesterol could not be observed during the combined treatment. Thus combined treatment could be particularly advantageous in the prophylaxis of arteriosclerotic complications of endogenous hypertriglyceridaemia, provided that contra-indications of either of the preparations are excluded.
D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010629:Phenformin / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D004338:Drug Combinations; D014280:Triglycerides; D002784:Cholesterol; D010629:Phenformin; D002994:Clofibrate
Die Kombination von Clofibrat und Phenformin in der Behandlung endogener Hypertriglyceridämien